Clinical trials
Prostate Cancer Stage clinical trials
Below are recruiting prostate cancer stage clinical trials, each written for real people, not researchers. We’re tracking 411 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT01194648Recruiting
HIFU treatment for early prostate cancer
This trial studies a focused ultrasound treatment called HIFU for prostate cancer that appears limited to the early stages. It aims to treat cancer within the prostate while avoiding treatment spread to lymph nodes or distant organs.
London, EnglandAges Up to 90 years - NCT05116475RecruitingPhase 3
New prostate cancer trial adding darolutamide to standard treatment
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
Chambray-lès-ToursAges 18–120 - NCT06665932Recruiting
Stereotactic radiotherapy for prostate cancer with smaller margins
This trial tests a precise radiation treatment for prostate cancer that uses smaller safety margins to reduce side effects while still targeting the cancer effectively. It may be a good option for people with early-stage, low- or favorable intermediate-risk prostate cancer.
Ostrava, Moravian-Silesian RegionAges 18 years+ - NCT07474142Recruiting
PSMA PET scan for newly diagnosed prostate cancer
This study looks at whether a special scan called PSMA PET can help predict how prostate cancer will progress. It is for people who have just been diagnosed and have not started treatment yet.
Lanzhou, GansuAges 18–100 - NCT07451795RecruitingPhase 2
SHR-1701 with targeted radiation for advanced prostate cancer
This trial tests a new drug called SHR-1701 combined with a precise type of radiation (SBRT) for men with prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to see if this combination can help control the cancer.
FujianAges 18–80 - NCT07300566Recruiting
Focal versus whole-gland radiation boost for localized prostate cancer
This trial compares two ways of giving a radiation boost (brachytherapy) to the prostate for men with localized prostate cancer. One method targets only the visible tumor, while the other treats the whole gland, and the study aims to see if the focal approach works as well with fewer side effects.
London, OntarioAges 18 years+ - NCT07190300RecruitingPhase 1/Phase 2
Study of tulmimetostat plus other hormone therapies for metastatic prostate cancer
This study tests two different combinations of drugs for men with prostate cancer that has spread to other parts of the body but still responds to hormone therapy. It compares a new pill (tulmimetostat) combined with standard treatments like darolutamide or abiraterone to see if it can help control the cancer longer.
Birmingham, AlabamaAges 18 years+ - NCT06949254Recruiting
Study of radiation and hormone therapy for high-risk prostate cancer
This study looks at combining stereotactic body radiation therapy (a precise type of radiation) with hormone therapy for men with high-risk prostate cancer that hasn't spread. The goal is to see how well this treatment works with fewer side effects.
Bergamo, BergamoAges 18 years+ - NCT06807359RecruitingPhase 1/Phase 2
Light-activated therapy for localized prostate cancer
This trial uses a special light-activated drug (photodynamic therapy) to treat prostate cancer that is still confined to the prostate. It aims to destroy the cancer while sparing healthy tissue, and may be an option for people with intermediate-risk prostate cancer who have not had other treatments.
New York, New YorkAges 18 years+ - NCT05520255RecruitingPhase 3
PSMA PET/CT scan to guide care after prostate cancer treatment
This Phase 3 study checks whether a PSMA PET/CT scan (using a special tracer) can help doctors make better decisions for people with prostate cancer after treatment, based on PSA blood test changes. It may help identify whether cancer has spread or how to plan next steps.
Edmonton, AlbertaAges 18 years+ - NCT07726602Recruiting
Tumor DNA blood test for muscle-invasive bladder cancer
This trial uses a blood test to look for small pieces of tumor DNA (ctDNA) after treatment for muscle-invasive bladder cancer. It aims to find out if the test can detect leftover or returning cancer earlier, helping guide next steps.
Portland, OregonAges 18 years+ - NCT06432036RecruitingPhase 1/Phase 2
Y90 Radioembolization for Early Kidney Cancer
This trial tests a treatment called Y90 radioembolization for people with early-stage kidney cancer who cannot have surgery or ablation. Tiny radioactive beads are delivered through a catheter to the tumor's blood supply to destroy it from the inside.
Los Angeles, CaliforniaAges 18 years+ - NCT06886321Recruiting
Testing a new non-surgical prostate cancer treatment
This trial tests a new, non-surgical treatment called irreversible electroporation (IRE) for men with early-stage prostate cancer that hasn't spread. It uses short electrical pulses to destroy cancer cells while sparing healthy tissue nearby.
Hong KongAges 40–85 - NCT05104515RecruitingPhase 1
First cancer vaccine test for advanced lung, ovarian, or prostate cancer
This Phase 1 study tests OVM-200, a new cancer vaccine, to see how it is tolerated and how it affects the immune system in people with advanced NSCLC, ovarian cancer, or prostate cancer. You may be eligible if your cancer has already had approved treatment(s) and no further standard options are planned within the first two months.
London, LondonAges 18–75 - NCT07017829RecruitingPhase 2
Combination therapy for STK11-mutant lung cancer
This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.
Buffalo, New YorkAges 18 years+ - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Birmingham, AlabamaAges 18 years+ - NCT06263153RecruitingPhase 2
Futibatinib and durvalumab before bladder cancer surgery
This trial tests two drugs (futibatinib and durvalumab) given before bladder removal surgery for people with muscle-invasive bladder cancer who cannot take standard cisplatin chemotherapy. The goal is to see if the combination shrinks the tumor and improves outcomes.
Ann Arbor, MichiganAges 18 years+ - NCT06104618RecruitingPhase 2
Enfortumab vedotin for advanced penile cancer
This trial tests a drug called enfortumab vedotin for people with advanced penile cancer (squamous cell carcinoma) that has spread or cannot be surgically removed. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Phoenix, ArizonaAges 18 years+ - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT05209243Recruiting
Treating limited-spread prostate cancer with radiation plus hormone therapy
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
MadridAges Any age - NCT07690306Enrolling by invitation
AI study to improve prostate cancer diagnosis with MRI and PSMA PET scans
This study is testing whether artificial intelligence can better predict prostate cancer by combining two types of scans (MRI and PSMA PET) along with your medical history, PSA, and biopsy results. If you have already had these scans and a biopsy, your information may help researchers develop a more accurate, non-invasive diagnostic tool.
Los Angeles, CaliforniaAges 18 years+ - NCT07163910RecruitingPhase 2
Homoharringtonine plus hormone therapy before prostate surgery
This trial tests whether adding a drug called homoharringtonine (a type of chemotherapy) to standard hormone therapy before prostate surgery can improve outcomes for men with certain stages of prostate cancer. It's for men who haven't had any previous treatment and plan to have their prostate removed.
Nanjing, JiangsuAges 18–85 - NCT05593497RecruitingPhase 2
Combination therapy before prostate surgery for high-risk prostate cancer
This study tests a combination of hormone therapy and a targeted drug before prostate surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach can improve outcomes.
West Los Angeles, CaliforniaAges 18 years+ - NCT05097274Recruiting
PET-CT scan for men with prostate cancer and a DNA repair mutation
This study uses a special scan (FCH-PET-CT) to help doctors see prostate cancer more clearly in men who have a known gene change involved in DNA repair. It’s meant to improve staging and assessment, especially around when imaging is needed.
London, Sutton, SurreyAges 18 years+
Hear when a new Prostate Cancer Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer stage?
- Yes. Clin2 currently lists 411 recruiting prostate cancer stage studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer stage trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer stage trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.